Evaluation of hepatocellular carcinoma development in patients with chronic hepatitis C by EOB-MRI

Table 3 Risk factors contributing to hepatocellular carcinoma incidence

Variable	Univariate analysis			Multivariate analysis
	Risk ratio	95%CI	P-Value	Risk ratio	95%CI	P-value
Age (per 1 year old)	1.04	1.01-1.09	0.045	1.05	0.99-1.11	0.139
Sex (F)	0.74	0.31-1.73	0.483
AST (U/L)	1.02	1.01-1.03	< 0.001	1.01	0.99-1.03	0.200
ALT (U/L)	1.01	0.99-1.02	0.12
Serum albumin (g/dL)	0.27	0.12-0.60	0.001	0.62	0.17-2.26	0.469
Gamma-GT (IU/L)	1.00	0.99-1.01	0.942
ALP (U/L)	1.002	1.001-1.004	0.006	1.00	0.99-1.01	0.504
T.Chol (mg/dL)	0.98	0.97-0.99	0.01	0.99	0.98-1.01	0.483
T.Bil (mg/dL)	2.01	0.77-5.25	0.153
PT (%)	0.97	0.94-0.99	0.018	1.01	0.97-1.05	0.621
Platelet (× 103/μL)	0.98	0.97-0.99	0.003	0.99	0.98-1.01	0.281
AFP (≥ 10 ng/mL)	7.39	2.97-18.37	< 0.001	3.10	1.03-9.35	0.045
LI (< 1.46)	11.63	2.71-49.9	0.001	6.05	1.34-27.3	0.019
≥ 1.601	1.00
1.501 to 1.60	2.68	0.17-42.9	0.48
1.381 to 1.50	7.24	0.89-58.9	0.06
1.311 to 1.38	11.5	1.2-103	0.02
≤ 1.31	17.34	2.16-138.7	0.007
Patients who received IFN	0.20	0.04-0.87	0.032	1.09	0.21-5.62	0.917
Patients who achieved SVR	0.35	0.81-1.51	0.158

AST: Aspartate amino transferase; ALT: Alanine aminotransferase; Gamma-GT: Gamma-glutamyl transpeptidase; ALP: Alkaline phosphatase; T.Chol: Total cholesterol; T.Bil: Total bilirubin; PT: Prothrombin time; AFP: α-fetoprotein; LI: Liver-intervertebral disc ratio; IFN: Interferon; SVR: Sustained virologic response; F: Female.